Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma
NCT07514819
Bone Diseases, Bone Neoplasms
Memphis, Tennessee, United States
View Trial DetailsNCT Number: NCT07337018
Bone can be the site of primary malignant tumors or, more commonly, secondary lesions. The most frequent primary tumors are osteosarcoma, chondrosarcoma, and Ewing sarcoma, whereas the malignancies that most commonly metastasize to bone include breast, prostate, lung, kidney, and thyroid cancers.
For the treatment of these conditions-and, in some cases, for locally aggressive benign diseases-a surgical approach is often required, which may result in substantial bone loss. Most commercially available prostheses commonly used in orthopedic surgery are not always suitable, either because of the anatomical location of the procedure or the type of resection planned, and thus the extent of the bone defect to be reconstructed. Therefore, specific prosthetic implants designed for oncologic surgery are required.
For this reason, modular prostheses have been developed, allowing reconstruction of bone defects of varying sizes across different anatomical districts. In recent years, the development and use of 3D-printing technology for producing custom-made prostheses has also increased, with the aim of reconstructing bone defects in areas that are difficult to treat and achieving an accurate reproduction of the patient's anatomy. This technology enables reconstruction in a wide range of skeletal sites. Additionally, it allows for preoperative planning on printed anatomical models and opens the possibility of integrating materials with adjuvant-related properties into the prosthetic design, such as photothermal therapy or antimicrobial features.
Although numerous studies on this topic are available in the literature, they frequently involve small patient cohorts. There is therefore a need to expand case series with longer follow-ups to better assess the reliability and effectiveness of these treatment strategies in the development of reconstructive orthopedic oncologic surgery.
Trial opening soon.
Get Notified30 year–70 year
All sexes
Observational
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Diagnosis of primary malignant or locally aggressive benign bone tumors, or secondary bone lesions with a primary diagnosis of breast, lung, prostate, kidney, or thyroid cancer;
Extensive bone loss precluding the use of currently available prostheses or standard surgical techniques;
Use of modular or custom-made prostheses produced with 3D-printing technology; minimum follow-up of 12 months;
(For patients in the retrospective phase) completion of evaluation questionnaires during outpatient follow-ups;
Obtaining Informed Consent, except for deceased patients enrolled in the retrospective phase of the study.
Exclusion criteria
Patients with disease spread to other bone segments;
Age <30 years or >70 years;
Patients who have undergone previous surgical procedures on the involved segment;
Follow-up of less than 1 year;
Incomplete clinical or radiological data sets;
Inability to obtain Informed Consent, except for deceased patients enrolled in the retrospective phase of the study
Time frame: From enrollment for at least one year
Postoperative quality of life and functional status assessed using the Karnofsky Performance Status score.
Time frame: At final follow-up
Postoperative functional outcome assessed using the Musculoskeletal Tumor Society (MSTS) scoring system.
Time frame: From enrollment for at least one year
Upper-limb functional outcome assessed using the QuickDASH questionnaire in patients with upper extremity involvement
Time frame: From enrollment for at least one year
Knee functional outcome assessed using the Oxford Knee Score in patients with knee involvement
Time frame: From enrollment for at least one year
Hip functional outcome assessed using the Harris Hip Score in patients with hip involvement.
Time frame: From enrollment for at least one year
Postoperative complications will be assessed through clinical evaluation and review of medical records, supported by imaging and laboratory findings when indicated. Complications include periprosthetic infection, implant loosening, wound dehiscence, dislocation (for implants including an articular component), and periprosthetic fracture. Each complication will be recorded as present or absent according to standard clinical diagnostic criteria
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Other
Valutazione Resezioni Oncologiche e Ricostruzione Con Utilizzo di Impianti Protesici in Chirurgia Oncologica Ortopedica (Evaluation of Oncologic Resections and Reconstruction Using Prosthetic Implants in Orthopedic Oncologic Surgery)
Acronym: RERIO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07514819
Bone Diseases, Bone Neoplasms
Memphis, Tennessee, United States
View Trial DetailsNCT05515068
Bone Diseases, Bone Neoplasms
View Trial DetailsNCT07325578
Bone Diseases, Bone Diseases, Metabolic
San Diego, California, United States
View Trial DetailsNCT06459141
Acute Normovolemic Hemodilution, Bone Diseases
Hangzhou, Zhejiang, China
View Trial Details